Search Index

Scientia News is full of STEM blogs, articles and resources freely available across the globe for students. Browse all of our fascinating content written by students and professionals showing their passion in STEM and the other sciences. Log In Welcome to Scientia News DELIVERING INFORMATIVE CONTENT Scientia News is full of STEM blogs, articles and resources freely available across the globe for students. Browse all of our fascinating content written by students and professionals showing their passion in STEM and other sciences. We hope this platform helps you discover something that inspires your curiosity, and encourages you to learn more about important topics in STEM. Meet the Official Team NAVIGATE AND CLICK THE PHOTOS BELOW TO LEARN MORE ABOUT US! To play, press and hold the enter key. To stop, release the enter key. To play, press and hold the enter key. To stop, release the enter key. To play, press and hold the enter key. To stop, release the enter key. Latest Articles chemistry The importance of symmetry in chemistry View More pharmacology ‘The Molecule’ by Dr Rick Sax and Dr Marta New View More biology What are health inequalities? View More neuroscience Does being bilingual make you smarter? View More CONTACT CONTACT US Scientia News welcomes anyone who wants to share their ideas and write for our platform. If you are interested in realising your writing potential with us AND live in the UK; and/ or would like to give feedback: Email us at scientianewsorg@gmail.com or fill in our GET IN TOUCH form below and we'll be in contact... Follow us on our socials for the latest updates. Comment, like and share! Join our mailing list below for latest site content. You can also sign up to become a site member . SUBSCRIPTION Join our mailing list to receive alerts for new articles and other site content. Be sure to check your spam/ junk folders in case emails are sent there. Email Subscribe GET IN TOUCH First Name Last Name Email Message Send Thanks for submitting!

Symmetry in spectroscopy, reaction mechanisms and bonding Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link The importance of symmetry in chemistry Last updated: 27/12/25, 17:26 Published: 08/01/26, 08:00 Symmetry in spectroscopy, reaction mechanisms and bonding Introduction Symmetry is everywhere- in snowflakes, flowers and even art. Chemistry is no different and the symmetrical properties of a molecule often dictate its behaviour. From interpreting spectra, to predicting reaction pathways and understanding bonding, symmetry shapes all chemical disciplines. 1. Symmetry in spectroscopy Firstly, understanding the symmetry of molecules is essential in a range of characterisation techniques. In 1 H NMR spectroscopy, the number of peaks seen in a spectrum correspond to the number of unique chemical environments. For example, dibenzylidene acetone has a plane of symmetry and a rotational axis (C 2 ) through the centre of the carbonyl. This explains why the spectrum only has 5 different proton environments. In IR spectroscopy, infrared radiation is absorbed by a molecule causing stretching and bending of bonds when they vibrate. The total number of vibrational modes can be predicted using: • 3N – 5 rule for linear molecules • 3N – 6 rule for non-linear molecules (where N = no. of atoms) However, only vibrations which cause a change in dipole moment are seen in IR spectra. This explains why CO 2 only shows 3 main absorption peaks, despite having 4 vibrational modes. 2. Symmetry in reaction mechanisms Considering the symmetry of molecules also helps chemists predict the stereochemical outcome of organic reactions. A common example is the E2 elimination of a halogenoalkane, where an alkene is formed via elimination of a halogen. For an E2 elimination to occur, the H and the leaving group must be 180 ° from each other, in an ‘anti-periplanar’ conformation. To predict which groups, have this relationship, Newman projections are used to easily assign and rotate bonds. A Newman projection is a perspective of a molecule, typically by imagining you are looking down a specific C-C bond. See Figure 3 . 3. Symmetry in bonding Lastly, considering the symmetry of a molecule is vital for understanding Molecular Orbital (MO) Theory. MO theory explains how covalent bonding occurs by considering the symmetry elements of the valence orbitals. For example, in H 2 , the two valence 1s orbitals are completely symmetric and therefore can overlap effectively to form a σ molecular orbital. However, in HF, the introduction of 2p orbitals means the shape and symmetry has changed. The 2p x and 2p y orbitals can no longer overlap with the 1s H orbital as their symmetries are incompatible. Using this information, a MO diagram can be constructed to show how the orbitals combine, explaining why H 2 has a single bond. In essence, symmetry determines which orbitals can ‘match up’ to form bonds. See Figure 4 . Conclusion Symmetry influences every aspect of chemistry and is frequently employed to rationalise observed molecular characteristics. While sometimes overlooked, considering the symmetry of a molecule underpins any chemistry undertaken across industry and academia. If you enjoyed this article, future articles could build on this topic by introducing Group Theory and showing how you can predict an entire vibrational spectrum, or the molecular geometry of a compound based entirely on its symmetry. Written by Antony Lee REFERENCES S. Civis, M. Ferus, A. Knizek, in The Chemistry of CO 2 and TiO 2 : From Breathing Minerals to Life on Mars, ed. S. Civis, M. Ferus, A. Knizek, Springer Nature, Switzerland, 1 st edn., 2019, vol. 1, ch. 1, pp. 1-7 A. Burrows, J. Holman, S. Lancatser, T. Overton, A. Parsons, G. Pilling, G. Price, in Chemistry 3 , Oxford University Press, Oxford, 3 rd edn., 2017, ch.4, pp. 172-219 Project Gallery

What they are, which groups are affected, and pandemic and economic impacts Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link What are health inequalities? Last updated: 27/12/25, 17:42 Published: 08/01/26, 08:00 What they are, which groups are affected, and pandemic and economic impacts This is Article 1 in a series on health inequalities. Next article: Socioeconomic health equalities (coming soon). Welcome to the first article in a series of articles about health inequalities. This first article will look more in detail at exactly what health inequalities are. Introduction Imagine that you lived in Blackpool, and that your friends or family lived in Kensington. Your life expectancy would be 76 years, while theirs would be 86 years, a full decade of difference! Or consider the fact that even though men have shorter life-spans compared to women, women spend longer living with ill health or major illnesses. These are some examples of health inequalities, which are health differences between different groups of people. They aren’t just random variations in health outcomes between different groups or people: instead, they’re systematic and avoidable. What groups are affected by health inequalities? Health inequalities can be seen across various populations. A person’s health can be impacted by socioeconomic factors, like income or wealth, and geographic factors, like where they live. Other characteristics affecting health include ethnicity or gender. These factors don’t act in isolation. For individuals who experience multiple levels of disadvantage, the effects of inequalities are worsened. For example, ethnic minority groups who live in deprived areas, or socioeconomically disadvantaged women, experience even worse health outcomes. This interconnectedness means that understanding health inequalities and addressing them requires a holistic approach. Health status and health inequalities Differences in health outcomes can manifest in different ways. One indicator is health status, which includes overall life expectancy and healthy life expectancy, which is the time people live in good health. In England, there’s an almost 10-year gap in life expectancy between the most and least deprived areas, shown by the example above, where the life expectancy is 76 years in Blackpool and 86 years in Kensington. Differences in healthy life expectancy between the most and least deprived areas are even more pronounced. Healthy life expectancy is more than 18 years lower for the most deprived areas compared to the least deprived areas, as shown in Figure 1 . Males living in the most deprived areas can expect to live 52.3 years in good health, while for males living in the least deprived areas, this number increases to 70.5 years. For females, it’s 51.9 years in the most deprived areas, compared to 70.7 years in the least deprived. The impact of the COVID-19 pandemic on health inequalities The COVID-19 pandemic has exacerbated health inequalities, with those living in the most deprived areas and people from ethnic minority backgrounds being the worst impacted. For example, as the pandemic strained healthcare services, more deprived areas had longer waiting lists, highlighting issues of unequal access and quality of care. In addition, death rates in the most deprived areas were higher compared to the least deprived areas: at a deprivation level of 1 (most deprived), deaths from COVID-19 were 566.2 per 100,000, with this number decreasing to 228.7 deaths per 100,000 at a deprivation level of 10 (least deprived), as seen in Figure 2 . The economic impact of health inequalities Health inequalities can have economic impacts as a result of the added costs needed to address them. The persistence of health inequalities, particularly among the working-age population, is a challenge to economic growth, as increasing levels of ill health can lead to economic inactivity. For example, data from before COVID-19 suggests that health inequalities cost the UK £31bn to £33bn per year in lost productivity, £20bn to £32bn per year in lost tax revenue and higher benefits payments and £4.8bn of the NHS budget. This is equivalent to almost a fifth of the NHS budget. As the pandemic exacerbated inequalities, these numbers have only increased: for example, the long-term impacts of COVID-19 have varied between demographics. Given that at least 2.5 million working-age adults are unable to work due to long-term sickness, as per the Office for National Statistics estimates, this is a significant economic challenge for the country, as well as a health issue. Conclusion Health inequalities have been shown to affect different groups disproportionately, with deprivation, ethnicity, socioeconomic status and other social factors having compounding effects, resulting in poorer health and shorter healthy lives. The COVID-19 pandemic further exacerbated these inequalities, with the most marginalised communities being the most affected. Failure to address these differences has resulted in not only human costs but also billions in lost productivity and increased burdens on health services. Socioeconomic status is one specific factor that influences health outcomes: as mentioned above, people in the most deprived areas face a gap of approximately ten years in life expectancy compared to the least deprived, seen when comparing life expectancy in Blackpool and Kensington. The next article in this series will look more in detail at socioeconomic inequalities, so watch out for that! Written by Naoshin Haque Related article: Global Health Injustices (series) Project Gallery

Discussing an upcoming biotech thriller book Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link ‘The Molecule’ by Dr Rick Sax and Dr Marta New Last updated: 02/01/26, 18:11 Published: 08/01/26, 08:00 Discussing an upcoming biotech thriller book Science, to some extent, is very black and white. You carry out experiments; you analyse the data, and you could use numerous techniques to get results. Although there is a range of techniques you could use to analyse and interpret the data, if it has been carried out correctly, the results should be reproducible. 1 + 1 will always equal 2, a eukaryote will always have a nucleus, and pure water will always have a boiling point of 100ºC. Once again, science is entirely black and white. But after an hour of conversation on a cold London afternoon, this writer can conclude that the life of a scientist does not have to be as black and white as their research. This is confirmed by looking at the fascinating lives of Dr Marta New and Dr Rick Sax. Dr Marta New Dr. Marta New's career spans the intersection of science and business, beginning with her PhD in Microbiology and Immunology from the University of Illinois Chicago. Demonstrating her versatility, she pursued an MBA at Northwestern University's Kellogg School of Management just two years later. Recognizing her passion extended beyond academia, Dr. New ventured into the business world, where she has held various influential roles. Her career includes positions as a venture capitalist at ARCH Venture Partners, board observer for numerous biotech companies, and strategic advisor to pharmaceutical firms. Dr. New's expertise lies in translating scientific breakthroughs into viable business opportunities, particularly in the areas of drug discovery and development. Currently, she is the founder and CEO of Radyus Research, a company focused on accelerating drug discovery through innovative AI-powered platforms. In this role, Dr. New continues to drive innovation and strategic growth in the biotech and pharmaceutical sectors, leveraging her unique blend of scientific knowledge and business acumen. Dr Rick Sax Dr. Rick Sax is a distinguished figure in the pharmaceutical industry with over 30 years of experience in senior leadership positions. His career spans across major pharmaceutical companies, including Merck & Co. and AstraZeneca, where he held executive roles in clinical development. At Merck, Dr. Sax led cardiovascular drug development and served on key business strategy teams. At AstraZeneca, he took on various leadership positions, including Vice President for U.S. Clinical Research and roles in global Medical Sciences. Dr. Sax later joined Quintiles (IQVIA) as Senior Vice President for Integrated Clinical Services, where he played a crucial role in developing innovative approaches to clinical program design and drug development strategies. His expertise encompasses drug research and development, clinical program design, translational medicine, and the application of information technology in clinical research. Currently, Dr. Sax serves as an advisor to biotechnology startups and consulting firms, leveraging his extensive experience to improve pharmaceutical R&D efficiency and productivity. Through their amazing expertise they have joined hands to write a biotech thriller called the ‘The Molecule’. What is the inspiration behind the novel The Molecule ? Science thrives on curiosity, discovery, and the pursuit of knowledge, often driven by a passion to understand the unknown. On the other hand, business is fueled by profit, efficiency, and the drive to deliver tangible results in the shortest possible time. The challenges can be immense in the biotech industry, where these two worlds must collide. Transforming a scientific breakthrough into a marketable product requires more than just innovation; it demands strategic thinking, financial acumen, and a deep understanding of the regulatory environment. The journey from lab bench to market shelf is fraught with obstacles, including securing funding, navigating complex regulations, and managing stakeholders' expectations with very different goals. In their new novel, The Molecule , authors Rick Sax and Marta New delve into the intricate world of drug development, breaking the conventional notion that this process is solely the domain of academia. The book explores the multifaceted journey of a startup company navigating the complex path of science, regulation, and industry. When asked about the inspiration behind the book, Rick and Marta emphasised their desire to shed light on the complex interplay between scientific innovation and the financial forces that drive it. They wanted to illustrate that drug development is a scientific endeavour and a battleground where researchers, regulators, and industry professionals often find themselves at odds. While The Molecule is a work of fiction, it brings a deep emotional resonance. The authors were keen to portray the technical challenges of developing a new drug and the human element—the hopes, fears, and sacrifices of those involved. Rick and Marta crafted a narrative that captures the struggles and triumphs, emphasising the complex journey of bringing a new drug to market. The book goes beyond the laboratory, vividly depicting the stages a startup company must navigate to succeed. It paints a realistic picture of the hurdles and setbacks often encountered along the way, making it a compelling read for anyone interested in the intersection of science, business, and human emotion. This biotech thriller also serves as a reminder that the fusion of science and business, though complex, is essential for driving progress and bringing life-changing innovations to the world. What is the drug development process, and what are the challenges? As mentioned, drug development is a long, arduous, and multifaceted journey. A journey that, in reality, is not limited to academia or clinical research. We must remember that drug development translates an idea into a drug in the market, a process that spans more than simple laboratory experiments. The book The Molecule gives us a glimpse of this process. As it turns out, there is a lot more that happens even before clinical trials begin. Unsurprisingly, the process of drug development began before "development". Instead, it starts as drug "discovery". Here, scientists wear their thinking hats to try and understand a disease, hoping to discover new insights or technologies that provide an approach to treatment. As Marta neatly outlined, scientists at this stage are surrounded by numerous questions, such as the drug's mechanism of action, how it works, etc. However, this discovery is not a finished product but rather a technology. Different questions must be asked to translate a fresh-off-the-lab technology into a marketable drug. Namely, "Is it safe and is it efficacious?" Next, the drug development journey will continue into the preclinical stage. Those who work in preclinical drug development may be familiar with the abundance of cell cultures and animal models used in this stage. Indeed, the preclinical stage often follows either or both in vitro and in vivo testing. Marta also highlighted another key factor, reproducibility. Crucially, a reproducible study refers to a repeated study done under different conditions or parameters and by other researchers where the results or analyses are the same or in agreement. Any study can be vulnerable to biases. Therefore, a reproducible study ensures fair, correct, and trustworthy results that allow scientists the confidence that the drug is safe before it enters clinical trials. Furthermore, testing the potential drug with a "standard of care" is equally essential. This means testing the candidate against an existing drug for the same disease. The process seeks to observe efficacy, whether the experimental drug is more efficacious than an already marketed drug. In other words, if the drug is working. As you can see, much work must be done before drug development reaches human testing. Preclinical studies may vary in size, but they are crucial in defining how safe the drug is before it is tested on people. Therefore, Rick and Marta emphasise that the preclinical stage must follow good practice and the correct guidelines, collecting data to paint a detailed pict ure before being given to the regulatory bodies. Upon the success of preclinical research and the approval of human testing by the regulatory bodies, a process that can take up to 5 years, we finally arrive at clinical trials. In short, clinical trials will further test the candidate drug on human subjects for safety and efficacy, dosage, side effects, and adverse reactions. As the trial progresses, the group size of each phase also increases, and as the number of human subjects increases, so does the cost. Rick and Marta explained that labs or smaller companies will usually carry out the preclinical research, but will search for larger pharmaceutical companies as partners to continue clinical trials. The drug development process is complex and concerns a multidisciplinary team of scientists, corporate partners, and regulatory bodies. However, this process is necessary to create a safe and effective drug that can change lives. Many science and STEM students gravitate only towards science and their respective passionate fields and, unfortunately, tend to find business intimidating. So, what would be your advice for these students to begin learning more about the business side of STEM and building their own start-up? The ideal way to answer this question is to consider it in two different parts: exploring a new passion (the world of business) and the advice to learn more. In many ways, one may always feel the vulnerability of exploring the unknown. Perhaps that is why we live following our passions: there is a certain security in their reliability and certainty for enjoyment and happiness. A safety blanket, so to speak. However, this very blanket could be the culprit that slowly suffocates all possibilities of growth, keeping you safe, secure, and immovable. By reading through their novel, The Molecule , and doing a Google search of these two writers' incredible lives, any reader can surely understand how to grow in pharmacology; there needs to be a specific element of business. Of course, for many, the thought of entering the clutches of the world of business, a world of numbers, negotiations, and a lack of laboratory equipment and sterilisation, might seem daunting. However, it is essential for any reader to understand that if they wish to enter the world of drug development, they will not find this door in academia. Instead, the key to drug development is built when different skill sets, areas of knowledge, and technical expertise come together through the work of a multipurpose team. This delicate and intricate process centres on the team, a team that requires multiple disciplines to work in harmony and in an environment where creativity may flourish. However, how can one go from understanding the importance of business in drug development to taking the first steps into this new, terrifying, and exhilarating world? The simple answer to this is explored in The Molecule . To succeed in the unknown, one must find a good mentor. Someone you truly believe in to show you the way. Of course, there should always be some caution in ensuring the right mentor is found. However, this should not hinder any keen reader from trying, as every experience can be an opportunity for growth. Furthermore, there are many positive stories of successful mentorships, as seen through Dr Sax’s personal experience. In the beginning, like many in STEM, he considered pharmacology “the dark side”. At the time, he worked at Cornell University Medical Centre, living the life many could only dream of. He spent his days working as a triple blend between a physician, a researcher, and a teacher – his passions. When first approached by a mentor on the possibility of pharmacology, a scene was conjured. A scene that showed the fiery pits of hell with the personification of pharmacology itself as a fearful villain pushing one into damnation. However, the support and encouragement from this mentor were the tiny pushes that convinced him to try, leading him to where he is today. There are many ways to find these mentors. Through academia, students can take advantage of programs such as hosting entrepreneurial activities, wet labs, organised panels, and events, such as “speak to a member of the industry”. Even exploring master programs in drug development could be a step forward in matching a student with potential mentors. Moreover, outside of the academic halls, there are many opportunities to form connections. By browsing LinkedIn groups, forums, and Reddit posts, you can find your people and see their steps. Following Dr. New’s humbling words, “It is important for students to remember they are not the first in the history of civilisation to think of entrepreneurship, and it is online where they can find signatures of the work others have done". "Your people" will be the ones that share your confusion, fear, perhaps lack of expertise, love for adrenaline, and a good challenge. Once you find them, everything will start flowing. Furthermore, consider how the real world works: if you want something, you need to go get it, be it with cold reach outs into the unknown and follow-up emails. On average, it takes 6 follow-up emails until someone replies to you. Hence, whatever you are doing, selling, or asking, do it 6 times before you give up. What vision do you see for the future of the biotechnology industry? When posed this question, both Fredrick and Marta conveyed that the future of biotechnology is heavily unpredictable, primarily due to the variability in the success of biotech startups. Moreover, one significant factor influencing this unpredictability is the funding which these firms receive. However, the changes in focus to new trends in biotechnology show great promise for how this large industry may grow and develop. For instance, a new trend is the considerable focus on rare diseases and targeted therapies for specific mutations such as the ALMK-14 mutation in lung cancer. There is also a significant focus on looking at disease subcategories and honing in on the specific type of disease. For example, instead of broadly targeting lung cancer, there is a trend towards addressing specific forms such as small cell lung cancer and non-small cell lung cancer. This precise approach aims to focus on specific characteristics of each disease’s subtype, for example, some forms of lung cancer may be more aggressive than others. Moreover, both Marta and Richard both highlighted the intertwining of biotechnology with other fields, specifically artificial intelligence (AI). An interesting example of this is utilising AI to develop targeted therapies for molecular markers of disease which may have been identified by lab techniques such as Next Generation Sequencing (NGS). Finally, the industry encompasses a wide range of professions from smaller pharmaceutical companies to larger pharmaceutical firms each with different focuses. Due to these varied focuses, the industry will likely develop and progress in diverse ways, reflecting the various aims of these firms. This diversity further reinforces the unpredictability of the industry’s future but also makes it an interesting field to watch. A massive thank you to Nick Johnstone for giving Scientia News this opportunity; it means a lot. We have learnt so many new things and it has been very inspiring talking to Rick and Marta. For more information, visit the following hyperlinks: Dr Rick Sax ( research ) Dr Marta New Nick Johnstone ( author ) Written by Inês Couto André, Jeevana Thavarajah, Stephanus Steven & Harene Elayathamby Related book reviews: Intern Blue , The Emperor of All Maladies Project Gallery

How diseases start and spread, the body’s defence system, vaccines, policies, and public opinion: unravel the maze of infection and immunity with these articles. Immunology Articles How diseases start and spread, the body’s defence system, vaccines, policies, and public opinion: unravel the maze of infection and immunity with these articles. You may also like: Biology , Medicine , Neuroscience , Chemistry COVID-19 misconceptions Common misconceptions during the COVID-19 pandemic Glossary of COVID-19 terms Key terms used during the COVID-19 pandemic A vaccine for malaria? A new hope for a vaccine for malaria The world vs. the next pandemic Can we see it coming? What steps do we need to take? Are pandemics becoming more severe? Arguments for and against Natural substances And how they can tackle infectious diseases A treatment for HIV? Can the CRISPR-Cas9 system be used as a potential treatment? The mast cell Key cells in the immune system Origins of COVID -19 How COVID-19 caused a pandemic Mechanisms of pathogen invasion How pathogens avoid detection by the immune system Astronauts in space How does little gravity affect the immune system? Ageing and immunity Ageing and its association with immune decline The impacts of global warming on dengue fever Dengue fever is a mosquito-borne Neglected Tropical Disease (NTD) Is the immune system 'selfish'? 'Selfish' genes from a Dawkins perspective, and the Modern Evolutionary Synthesis

Since 2006 when the link between amyotrophic lateral sclerosis (ALS), frontotemporal degeneration and TDP-43 mutations was demonstrated by Arai et al., it has remained a focus in neurological academia. This is for good reason; the research boom around the role of TDP-43 in neurodegeneration has elucidated links between TDP-43, parkinsonism and frontotemporal dementia (FTD). Go Back Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link TDP-43 and Me: the Neurodegenerative Impact of Gene Misplacement in Parkinsonism Last updated: 18/11/24 Published: 06/04/23 Practice and Progress in Neurology Since 2006 when the link between amyotrophic lateral sclerosis (ALS), frontotemporal degeneration and TDP-43 mutations was demonstrated by Arai et al., it has remained a focus in neurological academia. This is for good reason; the research boo m around the role of TDP-43 in neurodegeneration has elucidated link s between TDP-43, parkinsonism and frontotemporal dementia (FTD). The link between point mutations, deletions and loss of gene function in PRKN has long been established, but has yet to lead to the development of a targeted therapeutic treatment. PRKN is involved in the tagging of excess or faulty proteins with ubiquitin, which leads to degradation of the proteins in the ubiquitin/proteasome system (UPS)- a system characterised in medical neurology by its potential to cause serious neurological disorders. This places parkinsonism in a domain of neurodegenerative disorders sharing a common root in UPS dysfunction, including Alzheimer’s Disease, multiple sclerosis and Huntington’s Disease. Panda et al. (2022) demonstrated how the dysfunction of the UPS due to PRKN aberration inhibits the breakdown of the damaging TDP-43 aggregates which develop in human brains in response to mutation or stress. In healthy people, autophagic granules would attack and kill off these TDP-43 aggregates as an end result of the UPS , but due to aberrations in PRKN the UPS is inhibited in those afflicted with parkinsonism, causing neurodegeneration. The discovery of how TDP-43 and parkinsonism are linked could lead to the development of a treatment mimicking the organic catalyst of the TDP-43 aggregate breakdown to replicate UPS, reducing TDP-43 aggregate volume and by proxy, inhibiting neurodegeneration. In 2007, research by Esper et al. catalysed recognition of drug-induced Parkinsonism as severely underdiagnosed, with evidence proving even neurologists fail to effectively remember which medications cause parkinsonism. Fast halting of the inciting agent is necessary for the reversal of all parkinsonism symptoms, but in some patients, cognitive symptoms may persist for a time after the medication is stopped. In response to the novel discoveries of Panda et al. (2022), it is likely due to the aggregation of TDP-43. Another possibility is that permanent cognitive symptoms after inciting agent cessation in DIP may be due to large TDP-43 aggregates unable to be destroyed by the UPS. Further research will demonstrate whether TDP-43 aggregates become more resistant to UPS or autophagy through the progression of DIP, whether due to size or other extraneous factors. The implications of such a promising lead in neurotherapeutics for refractory parkinsonism cannot be understated. Surgical therapies have long since remained the industry standard in treating refractory parkinsonism, though this option remains prone to risk since many of those afflicted with parkinsonism are elderly, with drug-induced parkinsonism from treatment with antipsychotics, calcium channel blockers or other medications always heightening the number of the geriatric population requiring care for parkinsonism . Furthermore, the adequate treatment of those with parkinsonism in their youth could inhibit their progression to a refractory disease state in old age. Overall, the future looks very promising for those around the world suffering from all different forms of parkinsonism. Written by Aimee Wilson Related articles: A common diabetes drug treating Parkinson's disease / Lifestyle and PD risk

Tackling stereotypes and equal access Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link Why representation in STEM matters Last updated: 03/04/25, 10:38 Published: 13/03/25, 08:00 Tackling stereotypes and equal access In collaboration with Stemmettes for International Women's Month Representation in Science, Technology, Engineering, and Mathematics (STEM) and Science, Technology, Engineering, Art and Mathematics (STEAM), is crucial for everyone. Historically, STEM fields have been dominated by certain demographics that don’t show the true picture of our world. Maybe you grew up seeing no (or very few) women, people of colour, or other marginalised groups mentioned in your science curriculum. This needs to change because your voice, experiences and talents should be celebrated in any career you choose. Below, we’ll list some of the top reasons why representation is so important. Equal access Why does representation matter? Because it promotes equal access! Whether in an educational or career setting, seeing someone who looks like you do something you never thought possible can be life-changing. After all, you can’t be what you can’t see . Showing up in your role and sharing what you do or your STEM/STEAM interests show other people that these fields are accessible to everyone. Also, finding someone in a field you are (or would like to) get into is a great way to find a mentor, build a network, and boost your knowledge. Feeling excluded or discouraged is bound to happen at some point in your career, but anyone can succeed, no matter their background. Innovation When STEM fields are equally represented, better (and more innovative) ideas come to the table. Everything you’ve experienced can be useful in developing solutions to STEM and STEAM problems, no matter your level of education or upbringing. A lot of STEM doesn’t rely so much on your qualifications, but instead on your problem-solving, creativity, and innovation skills. For example, if you’re part of a culture that nobody else in your team has experienced, or you’ve experienced a disability and made adaptations for yourself, you bring a unique set of ideas to the table that can help solve many different problems. Inclusion There are many examples of when certain demographics haven’t been included in STEM decision-making processes. For example, many face recognition apps have failed to recognise the faces of people of colour, and period trackers have been made with misinformation about cycle lengths. If more diversity were seen throughout the process of creating a STEM product or service, we would see a lot fewer issues and a lot better products! Now, more than ever, your voice is important in STEM because science and technology are shaping the future at a fast rate. With the boom in artificial intelligence (AI) technology and its impact on almost every industry, we can’t afford to have models being trained from an unrepresentative data set. Look at people like Katherine Johnson, who despite facing setbacks as an African American at the time, was a pivotal part of sending astronauts aboard Apollo 11 into space. Or, more recently, Dr Ronx, who is paving the way as a trans-non-binary emergency medicine doctor. Tackling stereotypes Showing up in STEM & STEAM fields is a great way to tackle stereotypes. So many underrepresented groups are usually stereotyped into different career paths that are based on old, outdated notions about what certain people should do. By showing up and talking about what you love, you show that you’re not less capable than anyone else. Shout about your achievements, no matter how big or small, no matter where you are on your career journey so that we can encourage a new idea of what STEM looks like. Conclusion If this article hasn’t already given you the confidence to explore STEM and STEAM fields and all they have to offer, there are so many other reasons why you’re important to these fields and capable of achieving your dreams. Representation from you and others helps us create a more equitable, innovative, and inclusive future. It matters because the progress of science and society depends on the contributions of all, not a select few. Written by Angel Pooler -- Scientia News wholeheartedly thanks Stemmettes for this pertinent piece on the importance of representation in STEM. We hope you enjoyed reading this International Women's Month Special piece! Check out their website , and Zine / Futures youth board (The Stemette Futures Youth Board is made up of volunteers aged 15-25 from the UK and Ireland who will ensure the voices of girls, young women and non-binary young people are heard. They will work alongside the Stemette Futures charity board to guide and lead the mission to inspire more girls, young women and non-binary young people in to STEAM). -- Related articles: Sisterhood in STEM / Women leading in biomedical engineering / African-American women in cancer research Project Gallery

Jennifer Doudna and Emmanuelle Charpentier were jointly awarded the Nobel Prize in Chemistry in the year 2020, for their major contributions in reducing the number of components in the CRISPR-Cas9 system. An outline of their discovery CRISPR-Cas9 (clustered regularly interspaced short palindromic repeats) can be used, by removing, adding, or altering particular DNA sequences and may edit specific parts of the genome. Go Back Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link Who were the winners of the Nobel Prize in Chemistry in 2020? Last updated: 07/11/24 Published: 02/02/23 Jennifer Doudna and Emmanuelle Charpentier were jointly awarded the Nobel Prize in Chemistry in the year 2020, for their major contributions in reducing the number of components in the CRISPR-Cas9 system. An outline of their discovery Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR-Cas9) can be used, by removing, adding, or altering particular DNA sequences and may edit specific parts of the genome. A four-part mechanism called the Cas9 endonuclease consists of two small molecules. By combining these two RNA molecules into a "single-guide RNA," by Jennifer Doudna and Emmanuelle Charpentier, the Cas9 endonuclease was redesigned into a more manageable two-component system that could locate and cut the DNA target defined by the guide RNA- CRISPR/Cas9 ‘genetic scissors’. It can silence or activate genes as well as add or remove others. The Nobel Prize in Chemistry was awarded in 2020 in recognition of this contribution. Some advantages of this technology: quick easy adaptable innovative, unique Disadvantages: distribution challenges extremely conservative ethical issues some off-target effects some negative outcomes Significance of this discovery This discovery is important in preventing disease and is such a revolutionary tool. It does not just help humans but also animals, plants and even bacteria. CRISPR has already been applied to various disorders, such as cancer and infectious diseases. By making it possible to make changes to the target cells' genomes, which were previously challenging to do, the procedure offers a new perspective on biological treatment and demonstrates how important this tool is. But since this technology is still recent, scientists must develop straightforward processes and techniques to monitor and test its progress, performance, and outcomes. Jennifer Doudna Hailing from Washington DC., USA, Jennifer Doudna was born in 1964. As a professor of biochemistry, biophysics, and structural biology, Doudna’s main research focus is on RNA, and its variety of structures and functions. It was her research lab’s work that led to the discovery of CRISPR-Cas9 as an extraordinarily powerful tool to cut and edit the human genome to treat disease. This remarkable discovery was a decade ago in 2012, when Doudna and others were able to copy a bacterial system to create molecular scissors, in order to edit the genetic code. In October 2020, at the time of her being awarded the Nobel Prize in Chemistry, Doudna was affiliated to the University of Berkeley, in California. Emmanuelle Charpentier Coming from a French background, Emmanuelle Charpentier is a professor and researcher in microbiology, genetics, and biochemistry. Born in 1968, researcher Charpentier has made tremendous progress in her respective field. From being the director at the Berlin Max Planck Institute for Infection Biology in 2015, to founding her own independent research institute- the Max Planck Unit for the Science of Pathogens in the year 2018, and of course being jointly awarded the Nobel Prize in Chemistry in 2020; it is true that Charpentier has added new, valuable research in her work and has come a long way in her career. Why the CRISPR/ Cas9 system fascinates us We find CRISPR fascinating because as biological science students, we know this tool is vital for genetics and can help cure present incurable diseases such as sickle cell disease as well as cancer, showing what a revolutionary tool this is. It does not just help humans but also animals, plants and even bacteria showing how broad biology is and different fields can be linked to one another. Researchers are constantly coming up with new ways to use CRISPR-Cas9 gene editing technology to solve problems in the real world, such as epigenome editing, new cell and gene therapies, infectious disease research, and the conservation of endangered species. The advantages of this technology are that it is quick, easy and adaptable, but its disadvantages include distribution challenges, extremely conservative ethical issues, some off-target effects, and some negative outcomes. By making it possible to make changes to the target cells' genomes, which were previously challenging to do, the procedure offers a new perspective on biological treatment and demonstrates how important this tool is. Written by Jeevana Thavarajah, and Manisha Halkhoree Scientia News founder and managing director Related articles: Female Nobel prize winners in Chemistry and in Physics

Delving into the 'Nudge' effect by Thaler and Sunstein Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link Libertarian Paternalism and the ‘Nudge’ Approach Last updated: 05/11/25, 20:21 Published: 06/11/25, 08:00 Delving into the 'Nudge' effect by Thaler and Sunstein This is article no. 4 in a series on behavioural economics. Next article: Effect of time (coming soon). Previous article- Loss aversion . So far in our series of behavioural economics, we have discussed why and how people may make less favourable decisions than traditional economics assumes. We have spoken about how people can still be honest even when they are faced with a decision where they can be materially better off; and when someone loses their wallet, they feel more distaste than finding some money on the street; and how an endowment adds a bizarre sense of additional worth, that would cause you to think twice about trading it for something equally valuable. In today’s article, we are going to address why this is important to policy makers, and subsequently you and I, by exploring how governments and institutions can influence our decisions in ways that may seem paternalistic yet still respect individual freedom. This idea lies at the heart of libertarian paternalism . The idea behind the “Nudge” Nudge is a book written by Nobel Prize–winning economist Richard Thaler and legal scholar Cass Sunstein. Building on their 2003 paper, the book develops the idea that people’s choices can be shaped not only by the options available, but also by the context in which those options are presented — even by factors that seem trivial or irrelevant. This is where the concept of a “nudge” comes in: small design changes that steer people toward better decisions without restricting their freedom to choose. A simple change: the pension example A classic example comes from workplace pensions. Before 2008, when someone joined a new company, they were asked whether they wanted to join the company pension scheme. Most people didn’t — they took their full pay instead and failed to save for retirement. This created a growing problem for the government: an ageing population without enough savings to maintain a comfortable lifestyle. The solution was remarkably simple. Instead of asking employees to opt in to a pension, companies began enrolling them automatically, giving them the option to opt out instead. The choice remained exactly the same, pension or no pension, but the framing made all the difference. Opting out felt like losing something, and because people are naturally loss-averse, far fewer did so. In 2012, just under 50% of employees in the private sector had a pension. By 2018, after the introduction of auto-enrolment, that number had risen to around 80%. All from a change in default wording on a form. Libertarian Paternalism – a justification Paternalism is generally considered the situation where the government interferes in our choices, for better or for worse, much like a parent telling their children what they can and cannot do. In many cases, society accepts paternalism as necessary: we ban harmful drugs, make theft illegal, and impose safety regulations. But should governments really be meddling with our personal financial decisions? Should they be influencing our choices about pensions, spending, or saving? Whether they should or shouldn’t is ultimately a political question, not an economic one. However, what we can do is consider Richard Thaler and Cass Sunstein’s explanation of why policies such as pension defaults represent something fundamentally different. When the government restricts drugs or criminalises theft, it removes our freedom to choose — these are examples of hard paternalism, enforced by law. But with pensions, the government doesn’t force participation. The choice remains entirely yours: you can stay enrolled or opt out. This preservation of choice embodies the libertarian element — the freedom to decide for oneself. At the same time, by changing how the choice is presented, such as making enrolment the default option, policymakers can dramatically alter behaviour in a direction they consider beneficial. That is where the paternalistic element comes in. According to Thaler and Sunstein, this combination of freedom and gentle guidance is what defines libertarian paternalism . In Thaler and Sunstein’s eyes, nudging individuals towards better decisions through the use of policy is better and less controversial than implementing outright bans and mandates. It respects our autonomy while encouraging outcomes that they believe will improve collective welfare. If the government genuinely believes certain decisions are in the public’s best interest, then libertarian paternalism provides a way to influence behaviour without infringing on people’s right to choose. A question of freedom I do, however, pose some questions to you. If the government can influence your decision making through manipulating people’s psychology, can it truly be called libertarian ? And more fundamentally - does the government really know best? In recent years, the 'Nudge' approach has faced criticism, particularly regarding the assumptions it makes about what constitutes a “better” decision and who gets to define it. Despite this, the research continues to shape public policy across the world — from pensions and health to energy use and education. What’s crucial is that we remain aware of the ways our choices can be influenced. Recognising these nudges allows us to make decisions that best reflect our own values, circumstances, and goals. And on a deeper level, if every choice we make can be subtly shaped by those in power, how do we ensure that nudges serve the public interest — and not the interest of those who nudge? Written by George Chant Project Gallery

From the eyes of a chemist Facebook X (Twitter) WhatsApp LinkedIn Pinterest Copy link Polypharmacy: the complex landscape of multiple medications 10/07/25, 10:30 Last updated: Published: 21/09/24, 15:48 From the eyes of a chemist The concurrent use of many medications by a patient, known as polypharmacy, poses a complex challenge to modern healthcare, especially for the elderly and those with chronic diseases. Polypharmacy raises the risk of adverse drug responses, drug interactions, and medication non-adherence, even though it is essential for managing complicated health concerns. To maximise patient outcomes and guarantee safe treatment regimens, it is crucial to recognise the chemical interactions and effects of different medications. The chemistry behind polypharmacy Polypharmacy stems from the intricate interactions between several chemicals in the human body. Every drug has unique chemical components intended to interact with biological targets in order to provide therapeutic benefits. Nevertheless, when several medications are taken at once, their combinations may have unexpected effects. Understanding polypharmacy requires a thorough understanding of pharmacokinetics—the way the body absorbs, distributes, metabolises, and excretes medications—and pharmacodynamics—the effects of pharmaceuticals on the body. For example, some pharmaceuticals may cause or inhibit the enzymes that metabolise other drugs, changing the levels of the drug and possibly increasing its toxicity or decreasing its effectiveness. Analytical methods in polypharmacy management Chemistry offers a number of analytical and instrumental techniques for efficient polypharmacy management. Drug levels in the blood are tracked using methods like mass spectrometry (MS) and high-performance liquid chromatography (HPLC) to make sure they stay within therapeutic ranges. These techniques support dose modifications by identifying possible medication interactions. Furthermore, it is impossible to exaggerate the importance of chemistry in the creation of drug interaction databases and predictive modelling instruments. By helping medical professionals foresee and minimise harmful medication interactions, these materials help to ensure patient safety. The role of healthcare professionals To successfully manage the complexity of polypharmacy, healthcare professionals—including physicians, chemists, and nurses—need to have a solid understanding of chemistry. Their expertise is essential for assessing each drug's requirement, taking possible interactions into account, and coming up with methods to make drug regimens easier to follow. Managing polypharmacy is especially important for chemists. They assess patients' prescriptions, look for any interactions, and suggest changes or substitutes using their knowledge of medicinal chemistry. Pharmacists who participate in collaborative care can greatly lower the hazards related to polypharmacy. Innovations in medication management Chemistry-driven advances in medical technology are improving polypharmacy management. Real-time alerts regarding potential drug interactions can be provided to prescribers through computerised physician order entry (CPOE) systems that are coupled with clinical decision support systems (CDSS). Optimising polypharmacy may also be possible with the emergence of personalised medicine, which adjusts drug regimens according to a patient's genetic profile. Conclusion Polypharmacy remains a significant challenge in healthcare, demanding a comprehensive understanding of chemistry and pharmacology to manage effectively. Healthcare practitioners can minimise the hazards associated with several medications and provide safer and enhanced patient care by utilising modern analytical methods, prediction technologies, and multidisciplinary teamwork. Written by Laura K Project Gallery